Dermatol Ther. 2007 Jul-Aug;20(4):270-6.

Alefacept for the treatment of psoriasis and other dermatologic diseases.

Source

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA. Strober@nyc.rr.com

Abstract

Alefacept is a novel biologic agent for the treatment of plaque psoriasis. Alefacept is a fully human recombinant dimeric fusion protein composed of the terminal portion of Leukocyte Functioning Antigen-3 (LFA-3) and the Fc portion of human IgG(1). The drug likely works in part by inducing the apoptosis of memory effector (activated) T cells that play a central role in the pathophysiology of psoriasis. Alefacept also may interrupt the direct immunologic activation of T cells by antigen presenting cells. Alefacept is administered as a course of 12 intramuscular injections, but other dosing strategies have been explored. After a course of therapy, statistically more patients receiving alefacept achieve a psoriasis area and severity index (PASI) 75 response than those receiving a placebo. Some patients who achieve PASI 75 also experience long-term remissions from psoriasis. The drug is well-tolerated and adverse events are rare. Off-label use of the drug is growing and may be formally explored in the future.

PMID:: 17970892; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Alefacept: a novel biologic in the treatment of psoriasis. [Drugs Today (Barc). 2004]
Alefacept: a novel biologic in the treatment of psoriasis.
Liu CM, McKenna JK, Krueger GG. Drugs Today (Barc). 2004 Dec; 40(12):961-74.
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. [Arch Dermatol. 2003]
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, Alefacept Clinical Study Group. Arch Dermatol. 2003 Jun; 139(6):719-27.
Review Development and use of alefacept to treat psoriasis. [J Am Acad Dermatol. 2003]
Review Development and use of alefacept to treat psoriasis.
Krueger GG, Callis KP. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S87-97.
Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. [J Eur Acad Dermatol Venereol. 2003]
Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
Ortonne JP. J Eur Acad Dermatol Venereol. 2003 Jul; 17 Suppl 2:12-6.
Review Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis. [J Dermatolog Treat. 2007]
Review Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N. J Dermatolog Treat. 2007; 18(4):197-208.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Alefacept for the treatment of psoriasis and other dermatologic diseases.
Alefacept for the treatment of psoriasis and other dermatologic diseases.
Dermatol Ther. 2007 Jul-Aug ;20(4):270-6.

PubMed
Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in pa...
Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II.
Cancer Biol Ther. 2007 Jan ;6(1):22-9.

PubMed
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes...
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
Am J Hypertens. 2010 Mar ;23(3):334-9. Epub 2009 Dec 17 .

PubMed
A novel inhibitor of the alternative pathway of complement reverses inflammation...
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis.
J Exp Med. 2007 Jun 11 ;204(6):1319-25. Epub 2007 Jun 4 .

PubMed
Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleot...
Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.
Curr Pharm Des. 2005 ;11(22):2889-907.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: